$145.85
0.40% today
NYSE, Dec 24, 07:11 pm CET
ISIN
US4781601046
Symbol
JNJ

Johnson & Johnson Stock News

Positive
The Motley Fool
about 8 hours ago
Dividend-paying stocks are the gift that keeps on giving. They pay you a recurring stream of passive income that you can use to make new investments or cover some of your expenses.
Positive
Seeking Alpha
5 days ago
Johnson & Johnson's diversified revenue streams, significant presence in oncology and immunotherapy, and aggressive growth investments make it a strong defensive play. The company's low leverage, ample liquidity, and impressive free cash flow margin support its dividend sustainability and long-term growth. The stock is very attractively valued with an 18% potential upside.
Positive
24/7 Wall Street
5 days ago
The Dow Jones industrial average is a price-weighted index of 30 blue-chip U.S.
Positive
Seeking Alpha
6 days ago
The June/July, 2024 Fortune Magazine revealed 500 biggest U.S. companies by-revenue and profits. Arnold-research focused on 66 December industry-leaders using YCharts 12/13/24 data for Profits from 63. Those 63 Fortune 500 industry leaders (F500IL) were segmented into 21 business sectors ranging (alphabetically) from aerospace/defense to wholesalers. By yield, MO topped-all F500IL. Top-ten Yiel...
Positive
Reuters
6 days ago
The Johnson & Johnson drug Darzalex showed promise in helping keep a precancerous condition from progressing to the blood cancer multiple myeloma for those at high risk, according to results from a trial presented at the American Society of Hematology meeting in San Diego.
Positive
The Motley Fool
6 days ago
As an investor, your goal is to select quality stocks that will advance over a period of years -- but this doesn't mean you have to wait a long time for all of the rewards. If you add a few dividend stocks to your portfolio, you'll start collecting returns on a regular basis -- without lifting a finger.
Neutral
GlobeNewsWire
6 days ago
The European MCL Network Phase 3 TRIANGLE study, evaluated ibrutinib in combination with induction immunochemotherapy, both with and without an autologous stem cell transplant, followed by 24 months fixed-duration ibrutinib therapy1
Positive
Reuters
8 days ago
The U.S. Food and Drug Administration has declined to approve an injectable version of Johnson & Johnson's drug Rybrevant for a type of lung cancer, the drugmaker said on Monday.
Show more news

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today